Abstract 5989
Background
IP CT after upfront cytoreductive surgery has been the standard of care in EOC. Nevertheless, results from the recent GOG252 trial showed no impact of this strategy vesus IV CT in the concurrence of bevacizumab therapy. The aim of this study was to perform a meta-analysis of the survival benefit of IP vs IV CT after cytoreductive surgery including recent evidence.
Methods
A literature search in order to identify most relevant RCT comparing IV vs IP CT after cytoreductive surgery in EOC was performed. Non comparative studies or trials with no hazard or risk ratios were excluded. Statistical analyses were done using SPSS STATISTICS V.21. Fixed-effect meta-analysis for combining data was made. Degree of heterogeneity using the I2statistic was calculated. Endpoints meta-analysed were disease-free survival (DFS) and overall survival (OS).
Results
Initially 92 papers were identified. After exclusion criteria only nine RCT including pooled data from 3668 pts (2068 treated with IP CT and 1620 treated with IV CT) were included. In 8 RCTs IPCT was given after upfront surgery and in 1 (OV21/PETROC) after neoadjuvant CT. In all RCTs 6 CT cycles were foreseen in the IP arms. Seven RCTs including 3006 pts had DFS as endpoint. Among these, GOG252 cohorts A and B were analysed separately. IP CT showed a survival benefit over IV CT with HR = 0.86; (95% confidence interval (CI): 0.80 to 0.93). Heterogeneity was moderate (I2=37.3) Eight RCTs including 2289 pts had OS as endpoint. IP CT showed a significant impact on OS with HR = 0.81; 95% CI: 0.73 to 0.90). Heterogeneity was low (I2<0.01). Benefit of IP CT remained unchanged in the sensitivity analysis performed for both DFS and OS by eliminating the latest RCT of the meta-analysis.
Conclusions
IP CT benefits DFS and OS in this meta-analysis of pooled data from 9 RCTs and 3668 pts including latest negative results.
Clinical trial identification
Legal entity responsible for the study
Hospital Clinico Universitario de Valencia. INCLIVA.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3816 - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
Presenter: Nan Shen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5242 - Novel genomic classifier for early stage colorectal cancer patients
Presenter: Elisabeth Letellier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5404 - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Emanuela Romano
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5462 - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.
Presenter: Justine Cohen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5465 - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Presenter: Ignacio Matos Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Presenter: Maria Silvia Cona
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5790 - Effects of concomitant genetic alterations on cancer patient overall survival
Presenter: Yu Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer
Presenter: Dake Chu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?
Presenter: Rosalinda Sorrentino
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?
Presenter: Michela Terlizzi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract